Drug Type Trispecific T-cell engager (TriTE) |
Synonyms GPRC5D-BCMA-CD3 |
Target |
Mechanism BCMA inhibitors(B-cell maturation protein inhibitors), CD3 modulators(T cell surface glycoprotein CD3 modulators), GPRC5D modulators(G-protein coupled receptor family C group 5member D modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationFast Track (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Phase 1 | CN | 08 May 2024 | |
Myeloma recurrence | IND Approval | CN | 12 Mar 2024 |